Director of Clinical Operations Job Description

A Director of Clinical Operations is the person who makes a sponsor's clinical trials actually run. Clinical development decides what question a study should answer and medical writing turns that into a protocol; the clinical operations director owns everything after that: picking countries and sites, standing up vendors, hiring and directing the study teams, keeping enrollment on plan, and making sure the trial master file would hold up if an FDA investigator walked in tomorrow.

O*NET describes the occupation this job belongs to, Clinical Research Coordinators, as people who "plan, direct, or coordinate clinical research projects." At director level that work happens across a portfolio rather than a single study. A reporting line can run from clinical research associates and clinical trial assistants up through clinical trial managers and associate directors to the director, who in turn reports to a vice president of clinical operations or, at a smaller biotech, to the chief medical officer or head of development.

Much of the week goes to outsourced work. When a sponsor contracts out its studies, the director negotiates and governs relationships with contract research organizations, central and specialty labs, interactive response technology (IRT) providers, eCOA vendors, imaging core labs and patient recruitment firms. That means reading CRO change orders line by line, holding quarterly governance meetings, setting key performance indicators that matter (site activation time, screen failure rate, query aging, protocol deviations) and escalating early when a vendor drifts.

Money is the other constant. The director builds study budgets with finance, signs off on investigator grant templates and site contracts, tracks accruals each month, and explains variances to leadership before they become surprises. When two programs compete for the same senior trial manager or the same monitoring capacity, the director makes the call and documents why.

Quality sits underneath all of it. The director owns the clinical operations standard operating procedures, the deviation and CAPA process, the risk-based monitoring plan for each study, and inspection readiness for the trial master file. When an FDA inspection or a partner audit is announced, this is the person who runs the war room, prepares the study team for interviews and drafts responses to any observations.

The systems are concrete: a clinical trial management system (CTMS) for site and milestone tracking, an eTMF, electronic data capture (EDC) owned with data management, and IRT for randomization and drug supply. A good director knows these tools well enough to challenge a vendor's dashboard rather than accept it.

At a CRO, the same title points the other way: the director runs project delivery for sponsor clients, owning margins, staffing across studies and the client relationship, while the sponsor's own clinical operations team provides oversight.

Education. As a rough guide, the job starts from a bachelor's degree in a life science, nursing, pharmacy or a related health field. BLS says natural sciences managers, the broader occupation that includes clinical research leadership, typically need at least a bachelor's degree in a natural science or related field, and that most work as scientists before becoming managers. In clinical operations the earlier career is typically in trial execution rather than at the bench. A master's degree (MS, MPH, MBA) or a clinical doctorate such as a PharmD helps at some employers but does not replace a record of running studies.

Path and experience. A typical route runs clinical trial assistant or clinical research coordinator, then clinical research associate (monitor), clinical trial manager, associate director, then director. As a rough guide, candidates for director roles bring something like 10 or more years in clinical research, several of them leading study teams and managing CRO relationships directly. Strong candidates can point to evidence: a study taken from first patient in to database lock, a rescue of an underenrolling trial, a vendor replaced mid-study, an inspection survived without major findings.

Regulatory knowledge. Directors need working command of good clinical practice and the U.S. rules behind it: 21 CFR Part 50 (protection of human subjects, including informed consent), Part 56 (institutional review boards), Part 312 (investigational new drug applications) and Part 11 (electronic records and electronic signatures). Global programs also call for familiarity with each region's submission and transparency requirements, but the director's job is to know where to find the answer and who owns it, not to be the regulatory affairs lead.

Business skills. Budget forecasting and accrual accounting, contract negotiation, resourcing models, and the ability to brief a chief medical officer or a board in plain language.

Certifications. None is required by law. Credentials that clinical operations staff pursue include the Certified Clinical Research Associate (CCRA) and the ACRP Project Manager (ACRP-PM) from the Association of Clinical Research Professionals, the Certified Clinical Research Professional (CCRP) from the Society of Clinical Research Associates (SOCRA), and the Project Management Professional (PMP) from the Project Management Institute. At director level they complement a track record rather than replace it, and they signal that the candidate knows GCP formally rather than by habit.

Tools. Fluency with a CTMS and an eTMF, comfort reading EDC and query reports, and enough spreadsheet skill to rebuild a CRO's budget from its own assumptions.

BLS projects employment of natural sciences managers, the occupation that includes clinical research leadership, to grow 8 percent from 2025 to 2035, which it classes as much faster than the average for all occupations. It expects about 9,200 openings a year on average across the decade. Those figures describe the whole occupation, which O*NET's title list shows also covers laboratory directors and agricultural research directors; BLS does not report directors of clinical operations separately.

The biopharma hiring picture has been uneven. BioSpace's 2026 U.S. Life Sciences Employment Outlook, based on a survey late in 2025 of 136 professionals with insight into talent acquisition or workforce planning, found that 64% of respondents were actively recruiting, up from 59% in the 2024 survey. Research and development led the list of functions respondents expected to add, and clinical came next at 48%. The same report counted made or projected workforce cuts affecting about 42,700 employees in 2025, a 47% jump from 2024 by BioSpace's tally, a count that excludes contract research organizations. Both figures matter to anyone job hunting at director level: recruiting activity rose in the survey even as the 2025 layoff count climbed.

On the regulatory side, FDA's guidance on artificial intelligence for drug and biologic sponsors remains a draft. In January 2025 FDA released draft guidance, Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products, which proposes a risk-based credibility assessment framework for AI models. The draft does not address AI used for operational efficiencies, such as internal workflows or resource allocation, that do not affect patient safety, drug quality, or the reliability of study results. For clinical operations leaders, that line matters: an AI tool that drafts a monitoring visit letter looks like an internal workflow, while a model that decides which data points get source verification may touch the reliability of results, and the director has to be able to tell the difference and document it.

Efficiency has been a sore point for the workforce itself. In ACRP's Voices from the Frontlines survey, conducted from December 2024 to February 2025 with more than 735 respondents across sites, academic research organizations and CROs, only 33% said trial operations are efficient industry-wide, and 31% said budgets are sufficient to support good study operations. Those are the problems a clinical operations director is hired to fix, whether through better vendor terms, smarter monitoring plans or a cleaner start-up process.

Advancement can lead to senior director, then vice president of clinical operations, and at some companies to head of development operations or chief operating officer. Directors can also move between sponsors, CROs and site networks, where the same portfolio, vendor and inspection skills apply. Anyone weighing a move should look hard at a company's pipeline and funding runway before signing on to build a team.

Dear Hiring Committee,

I am applying for the Director of Clinical Operations position at Northpoint Therapeutics. For the past six years I have led clinical operations for two oncology programs at a mid-size biotech, and the chance to build the function for a company moving its lead asset into a pivotal study is exactly the work I want next.

In my current role I manage a team of nine: three clinical trial managers, four CRAs and two clinical trial assistants, plus the oversight of a full-service CRO across 60 sites in North America and Europe. When our Phase 2 study fell behind on enrollment, I rebuilt the site list with the medical team, closed the sites that had not screened anyone in four months, and moved monitoring to a risk-based plan with centralized review of key data. We reached last patient in on the revised date and locked the database five weeks later.

I also own our vendor governance. I renegotiated the CRO's monitoring and project management line items after a budget review, set quarterly scorecards for our IRT and central lab vendors, and replaced an eCOA provider mid-study without losing data. Our study team went through an FDA inspection of a lead site last spring, and I ran the preparation, from the TMF quality check to mock interviews.

What draws me to Northpoint is the chance to set up the SOPs, systems and partnerships before the pivotal program starts, rather than retrofitting them under deadline. I would welcome the chance to talk through how I would approach your first 12 months of start-up.

Thank you for your consideration.

Sincerely, Jordan Ellis